View source for BL22

{{SI}}
{{CMG}}

{{EH}}

'''BL22''', also called CAT-3888 or GCR-3888, is an [[immunotoxin]] which attaches to and, upon internalization, kills [[B cell]]s.  It has completed a Phase I clinical (human) trial and is currently in a [[Phase II]] clinical trial for the treatment of [[hairy cell leukemia]] at a Phase I clinical trial for pediatric [[acute lymphoblastic leukemia]] and [[non-Hodgkin's lymphoma]][http://clinicaltrials.gov/ct/show/NCT00077493?order=2] at the [[NIH]] in the U.S.  It may be useful against any B cell [[leukemia]] or [[lymphoma]].

Technically, BL22 is an anti-CD22 immunotoxin fusion protein between a murine anti-CD22 disulphide-linked Fv (dsFv) [[ fragment antigen binding|antibody fragment]] and an edited copy of bacterial Pseudomonas exotoxin PE38.  The toxin is activated intracellularly, by the low [[pH]] of the [[lysosome]] into which the entire protein was internalized via the CD22 receptor.  The toxin kills the targeted cell through [[ribosome]] inactivation.[http://www.biospace.com/news_print.aspx?NewsEntityId=1132]

BL22 is very similar to the newer HA22, which changes one amino acid in the antibody fragment to increase the binding affinity for the target molecule.  Both of these proteins are designed to bind to the [[CD22]] receptor on the surface of B cells.

==Business History==
BL22 was initially designed and produced at the U.S. [[National Cancer Institute]], one of the agencies which make up the [[NIH]].  Early development of BL22 was funded by California biotech [[Genencor]].[http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-01-2005/0004204747&EDATE=]  The future drug was acquired by Cambridge Antibody Technology at the end of 2005; less than a year later, CAT was purchased by British pharmaceutical company [[AstraZeneca]].[http://www.astrazeneca.com/pressrelease/5266.aspx]

{{SIB}}

[[Category:Cancer treatments]]
[[Category:Chemotherapeutic agents]]
[[Category:Hematology]]
[[Category:Orphan drugs]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}